Skip to content

TransMedics Group, Inc. TMDX Non Us — Revenue

Similar metrics at other companies

Pool Corporation logo
POOLNon Us — Revenue
$97.23M+4.0%
ePlus logo
PLUSNon Us — Revenue
$23.17M+8.6%
First American Financial logo
FAFNon Us — Revenue
$131.88M+25.2%
Axcelis Technologies logo
ACLSNon Us — Revenue
$175.5M-19.7%
Enova International logo
ENVANon Us — Revenue
$23.6M+32.7%
Universal Display logo
OLEDNon Us — Revenue
$137.48M-13.7%

Other financials

Income statement

See full
Revenue$173.9M+21.2%
Gross profit$101.2M+14.7%
Operating income$13.3M-51.5%
Net income$7.3M-71.5%
EPS (diluted)$0.20-71.4%

Balance sheet

See full
Cash & equivalents$461.7M+48.9%
Total debt$409.9M+505%
Total equity$494.0M+85.5%
Total assets$1.4B+71.3%

Cash flow

See full
Operating cash flow$24.5M+959%
CapEx$36.7M+35.6%
Free cash flow-$12.1M+59.4%

Valuation

See full
Market cap$2.55B+50.6%
Enterprise value$2.5B+66.0%
P/E14.8×-19.8×
P/S+0.5×

Profitability

See full
Gross margin59.1%-0.4pp
Operating margin14.9%+4.1pp
Net margin27%+17.0pp
FCF margin23.8%

Returns & leverage

See full
Return on equity45.2%+22.2pp
Debt / equity0.8×+0.6×
Current ratio6.7×-2.4×

Where this comes from

Reported directly by TransMedics Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:Revenues.

The official record: TransMedics Group, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →

Ask your AI about TransMedics Group, Inc.'s non us — revenue.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is TransMedics Group, Inc.'s non us — revenue?
TransMedics Group, Inc. (TMDX) reported non us — revenue of $5.65M in Q1 2026.
What does non us — revenue mean?
This metric represents the total revenue generated from sales and services provided to customers located outside of the company's primary domestic market. It serves as a key indicator of the company's international market penetration and the global scalability of its medical technology solutions. Monitoring this figure helps investors assess geographic diversification and the success of expansion strategies into foreign healthcare systems.